List of Excipients in Branded Drug DRAX EXAMETAZIME

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Jubilant DraxImage Inc dba Jubilant Radiopharma	DRAX EXAMETAZIME	kit for the preparation of technetium tc 99m exametazime for leukocyte labeling	65174-200	NITROGEN
Jubilant DraxImage Inc dba Jubilant Radiopharma	DRAX EXAMETAZIME	kit for the preparation of technetium tc 99m exametazime for leukocyte labeling	65174-200	SODIUM CHLORIDE
Jubilant DraxImage Inc dba Jubilant Radiopharma	DRAX EXAMETAZIME	kit for the preparation of technetium tc 99m exametazime for leukocyte labeling	65174-200	STANNOUS CHLORIDE

DRAX EXAMETAZIME Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

DRAX EXAMETAZIME is a technetium-99m exametazime radiopharmaceutical kit. Its commercial value depends less on the active ligand itself than on kit stability, radiochemical purity, preparation time, operator safety, and compatibility with hospital radiopharmacy workflows. The core excipient platform is expected to include a reducing agent, tonicity agent, buffering or pH-control components, and an inert atmosphere or lyophilized presentation. Public product information for comparable exametazime kits identifies stannous chloride and sodium chloride as principal non-active ingredients.[1,2]

The strongest commercial opportunities are improved shelf life, lower radiochemical impurity formation, simplified reconstitution, reduced vial waste, and differentiated ready-to-use or unit-dose presentations. Broad composition-of-matter patent protection is unlikely to remain commercially relevant because exametazime and the established kit technology have been marketed for decades. Protection is more likely to arise from formulation, manufacturing, packaging, stability, device, or process claims.

What is DRAX EXAMETAZIME and how is it used?

DRAX EXAMETAZIME is a kit used to prepare technetium Tc-99m exametazime injection. Exametazime is also known as hexamethylpropyleneamine oxime, or HMPAO. After labeling with sodium pertechnetate Tc-99m, the preparation is administered intravenously for nuclear medicine imaging.

The principal clinical uses of Tc-99m exametazime include:

• Cerebral perfusion imaging.
• Localization of infection or inflammation using labeled autologous leukocytes.
• Selected applications involving white blood cell distribution and inflammatory disease.

The product is generally supplied as a sterile, non-radioactive kit. The hospital or radiopharmacy adds sodium pertechnetate Tc-99m immediately before administration. This makes the excipient system important because the formulation must support both chemical stability before labeling and radiochemical stability after labeling.

What are the core formulation components?

Public information for the established Ceretec exametazime kit identifies the following components:

Component	Function
Exametazime	Technetium-binding ligand and active pharmaceutical ingredient
Stannous chloride dihydrate	Reducing agent that converts technetium into a form suitable for complexation
Sodium chloride	Tonicity and formulation-support excipient
Nitrogen or inert atmosphere	Limits oxidation during storage
Sodium pertechnetate Tc-99m	Added at the radiopharmacy; radioactive labeling reagent rather than a prefilled kit excipient

The precise DRAX EXAMETAZIME composition, fill weight, container closure, residual moisture specification, and nitrogen headspace should be assessed against the applicable Canadian product monograph or other jurisdiction-specific regulatory record. Excipients cannot be treated as interchangeable across products because changes can affect labeling yield, impurity profile, sterility assurance, shelf life, and clinical handling.

What excipient strategy is most important for exametazime?

The central strategy is oxidation control. Exametazime kits contain a reducing system because the technetium-labeling reaction is sensitive to the oxidation state of technetium and to degradation of the ligand. Stannous chloride is therefore both a functional excipient and a potential source of stability risk.

How does stannous chloride affect product performance?

Stannous chloride supports reduction of pertechnetate and helps form the Tc-99m exametazime complex. Its performance can decline through oxidation, moisture exposure, interaction with the container closure, or degradation during storage.

Commercial formulation objectives include:

1. Maintaining sufficient reducing capacity through the labeled shelf life.
2. Limiting insoluble tin or hydrolysis-related particles.
3. Preserving radiochemical purity after reconstitution.
4. Minimizing variability between manufacturing lots.
5. Maintaining performance after transport and handling by hospital pharmacies.

A formulation that uses less stannous chloride is not automatically superior. Excess reducing agent can also affect impurity formation, labeling behavior, or product consistency. The relevant commercial target is the lowest effective concentration that preserves radiochemical performance across the validated shelf life and operating range.

What role does sodium chloride play?

Sodium chloride supports isotonicity and may help maintain the physical characteristics of the reconstituted preparation. In a lyophilized kit, the quantity is typically modest, and its value is functional rather than proprietary.

Sodium chloride alone is unlikely to create meaningful patent differentiation. Its commercial relevance comes from interaction with the full formulation, including:

• Residual moisture.
• Reconstitution volume.
• pH.
• Stannous chloride concentration.
• Container closure.
• Tc-99m activity and concentration.
• Post-reconstitution hold time.

A claim directed only to sodium chloride concentration would likely face novelty and obviousness challenges unless tied to a demonstrated stability or labeling advantage.

What formulation patents could protect DRAX EXAMETAZIME?

The most defensible patent targets are narrow formulation and process claims supported by comparative data. Potential claim areas include:

Patent target	Commercial rationale	Relative patent strength
Stannous chloride concentration range	Controls labeling efficiency and impurity profile	Moderate if linked to unexpected stability data
Buffer or pH-control system	May improve post-reconstitution stability	Moderate
Lyophilized cake composition	Supports rapid and complete reconstitution	Moderate
Residual moisture specification	Protects shelf life and reducing capacity	Moderate to strong if technically correlated
Inert-gas fill and oxygen specification	Limits oxidation	Moderate
Container closure system	Controls moisture and oxygen ingress	Moderate
Reconstitution method	Reduces preparation errors and variability	Moderate
Ready-to-use Tc-99m formulation	Reduces radiopharmacy labor and waste	Potentially strong, but technically demanding
Unit-dose or multi-dose packaging	Improves workflow economics	Moderate
Automated dispensing cartridge	Protects device and product integration	Stronger if the system is difficult to design around

The strongest portfolio would combine composition, manufacturing, packaging, and use claims. A single excipient patent would leave the commercial product vulnerable to design-around strategies.

What manufacturing and IP barriers affect the kit?

Key manufacturing barriers include:

• Control of stannous chloride oxidation.
• Low-moisture lyophilization.
• Sterile filtration or aseptic filling.
• Consistent cake structure.
• Container closure integrity.
• Control of radiochemical impurities after labeling.
• Validation across different sodium pertechnetate generators.
• Stability after exposure to shipping temperature excursions.

A patent strategy can protect the relationship between these variables. For example, a claim covering a specific stannous chloride range, residual moisture range, nitrogen headspace, and post-reconstitution radiochemical purity would be more commercially useful than a generic claim to a kit containing exametazime and stannous chloride.

When does exametazime lose exclusivity?

Exametazime is an established small-molecule radiopharmaceutical. The original active-ingredient and early kit patents are likely expired or commercially weak in major markets. The relevant exclusivity question is therefore not whether exametazime has basic exclusivity, but whether DRAX EXAMETAZIME has current product-specific patents, regulatory exclusivity, or proprietary manufacturing controls.

Exclusivity category	Likely status for established exametazime technology
New chemical entity exclusivity	Expired
Original composition patents	Generally expired or near the end of practical relevance
Basic kit formulation patents	Likely expired or vulnerable to prior art
Current formulation patents	Possible if directed to a later improvement
Method-of-use patents	Possible, but narrow and jurisdiction-dependent
Regulatory exclusivity	Generally limited for an established radiopharmaceutical
Trade-secret protection	Potentially significant for lyophilization and process controls
Device or automation protection	Potentially available for newer delivery systems

Patent expiration dates should be confirmed by jurisdiction-specific patent-family review. The product name alone does not establish the patent estate, Orange Book status, or launch exclusivity.

What is the Orange Book status of exametazime?

The Orange Book is primarily relevant to FDA-approved drug products subject to abbreviated new drug application procedures. A radiopharmaceutical kit may have an FDA listing, but the practical availability of Orange Book patent and exclusivity information depends on the specific approved product, NDA, dosage form, and current marketing status.

For a U.S. market assessment, the relevant checks are:

1. FDA Drugs@FDA for the approved exametazime NDA.
2. Orange Book product and patent listings.
3. FDA labeling and approval history.
4. Current manufacturer and marketing status.
5. Applicable generic or 505(b)(2) pathways.

A product-specific Orange Book listing should not be assumed for DRAX EXAMETAZIME without confirmation in the FDA database. The Canadian product status is governed by Health Canada, including the Drug Product Database and applicable product monograph.[3]

Are Paragraph IV challenges relevant to DRAX EXAMETAZIME?

Paragraph IV litigation is possible only if an eligible U.S. reference product has listed patents and a competing applicant files an ANDA with a Paragraph IV certification. The risk appears lower for an old exametazime kit than for a recently approved conventional drug because:

• The active ingredient is established.
• The principal kit technology is mature.
• Early patents are likely expired.
• Radiopharmaceutical manufacturing requires specialized facilities.
• Commercial demand is smaller than for mass-market oral or injectable drugs.
• A competing applicant may choose a 505(b)(2) strategy if formulation or labeling differences are material.

The more realistic challenge would involve a product-specific formulation or process patent rather than a broad exametazime patent. Litigation risk would rise if the sponsor listed new patents covering reconstitution, stability, packaging, or an automated Tc-99m labeling system.

What generic entry risks exist for DRAX EXAMETAZIME?

Generic entry risk is moderate from a legal perspective but constrained by technical and commercial barriers.

Generic or follow-on product scenarios

Scenario	Entry characteristics	Risk to incumbent
Same kit composition	Direct competition on price and supply	High if approved
Alternative stannous formulation	Requires comparative stability and labeling data	Moderate
Different lyophilization process	Potential design-around	Moderate
Ready-to-use Tc-99m product	Higher development cost, workflow advantage	Moderate
Hospital-compounded alternative	Limited by regulatory and quality requirements	Low to moderate
505(b)(2) product with modified preparation	May avoid some formulation barriers	Moderate
Regional radiopharmacy preparation	Competes locally, subject to radiation and compounding rules	Low to moderate

The key barriers are not only patents. They include validated sterile manufacturing, access to radionuclide supply, product release testing, short radiological shelf life, and hospital procurement relationships.

How can excipients create commercial opportunities?

1. Longer non-radioactive shelf life

Improved oxygen and moisture control could extend the kit’s shelf life or reduce potency drift. This has direct value because unused kits are costly when radiopharmacy demand fluctuates.

Potential technologies include:

• Lower-permeability vial stoppers.
• Improved aluminum seal systems.
• Nitrogen backfilling.
• Lower residual moisture.
• Oxygen scavenger packaging, subject to compatibility and regulatory acceptability.
• More robust lyophilization cycles.

2. Faster reconstitution

A kit that dissolves rapidly and completely can reduce technologist time and preparation delays. The opportunity is strongest where current products require repeated agitation, waiting periods, or visual inspection.

Protectable features could include cake morphology, excipient ratios, vial geometry, or a reconstitution protocol.

3. Higher radiochemical purity

Improved purity can reduce repeat preparation, rejected doses, and uncertain imaging quality. A formulation program should measure:

• Percentage of Tc-99m exametazime complex.
• Hydrolyzed or reduced technetium.
• Free pertechnetate.
• Lipophilic and non-lipophilic impurities.
• Stability during the approved post-labeling period.

Radiochemical purity data are central to both regulatory approval and patent strength.

4. Lower radiopharmacy waste

Waste reduction can be achieved through:

• Smaller kit sizes.
• Unit-dose packaging.
• Multi-dose vials with validated withdrawal limits.
• Longer post-reconstitution stability.
• Flexible activity loading.
• Improved compatibility with automated dispensing systems.

The economic value depends on hospital throughput, generator size, patient scheduling, and local reimbursement.

5. Ready-to-use or automated systems

The largest product opportunity is a ready-to-use or semi-automated Tc-99m exametazime platform. Such a product could reduce operator exposure, preparation variability, and training requirements.

Development barriers include:

• Tc-99m decay and logistics.
• Generator compatibility.
• Sterility.
• Dose calibration.
• Container shielding.
• Radiochemical stability.
• Device qualification.
• Transportation and handling controls.

The resulting IP portfolio could include the formulation, cartridge, fluid path, shielding assembly, automated mixing process, and software-controlled preparation sequence.

How does DRAX EXAMETAZIME compare with competing imaging agents?

Exametazime competes with other nuclear medicine agents based on clinical indication, availability, preparation complexity, and radiopharmacy economics.

Product class	Main advantage	Main limitation
Tc-99m exametazime	Established cerebral perfusion and labeled-leukocyte applications	Kit preparation and stability requirements
Tc-99m HMPAO alternatives	Similar clinical utility where available	Limited differentiation between products
Tc-99m bicisate	Cerebral perfusion imaging	Does not provide the same leukocyte-labeling profile
FDG PET	Broad metabolic imaging capability	Requires PET infrastructure and higher operational complexity
In-111 labeled leukocytes	Established infection imaging	Longer half-life and different workflow
Gallium-67 products	Infection and inflammation imaging	Slower imaging schedule and less convenient logistics

Excipient-based differentiation is most valuable where the clinical agent is otherwise difficult to distinguish. A sponsor can compete through preparation reliability, supply continuity, labeling performance, and total radiopharmacy cost.

Which companies are potential competitors or partners?

The competitive field includes established radiopharmaceutical manufacturers, generic injectable companies, hospital radiopharmacies, and kit or device developers. Relevant commercial categories include:

• DRAXIMAGE and Drax-related radiopharmaceutical operations.
• GE HealthCare, historically associated with Ceretec exametazime.
• Curium and other nuclear medicine suppliers with Tc-99m products.
• Regional radiopharmaceutical manufacturers.
• Generic sterile injectable companies with radiopharmacy capabilities.
• Automated compounding and dose-management companies.

Licensing opportunities are most credible for a company that has one of four assets: a validated low-oxygen lyophilization process, a superior container closure, a ready-to-use radiolabeling platform, or an automated dispensing system. A conventional excipient substitution would have lower licensing value unless supported by clear stability, workflow, or cost advantages.

What is the commercial value of an improved excipient platform?

The revenue opportunity is concentrated in recurring institutional use rather than consumer demand. Commercial value can be modeled through:

• Number of nuclear medicine sites.
• Annual exametazime kit volume per site.
• Percentage of doses lost to expiry or failed preparation.
• Labor time per preparation.
• Price premium for higher stability or convenience.
• Reimbursement and procurement dynamics.
• Competitive availability of alternative kits.

A formulation that adds a modest price premium but reduces preparation failures and waste can be commercially attractive. A high-cost reformulation without workflow savings would face adoption resistance because hospitals often purchase radiopharmaceutical kits through price-sensitive tenders.

Key Takeaways

• DRAX EXAMETAZIME is a Tc-99m exametazime kit whose performance depends heavily on excipient and packaging control.
• Stannous chloride is the critical functional excipient because it supports technetium reduction and labeling.
• Sodium chloride has formulation and tonicity value but limited standalone patentability.
• The strongest IP opportunities are formulation-process combinations, residual-moisture controls, container closure systems, and automated labeling platforms.
• Original exametazime composition protection is unlikely to provide meaningful current exclusivity.
• Paragraph IV risk is less important than 505(b)(2), regional follow-on, and specialized radiopharmaceutical competition.
• Commercial differentiation should focus on shelf life, radiochemical purity, rapid reconstitution, lower waste, and reduced operator burden.
• Ready-to-use and automated Tc-99m exametazime systems offer the highest potential value but also the greatest technical and regulatory burden.
• Publicly accessible data should not be used to assume that DRAX EXAMETAZIME has the same exact excipient quantities or patent position as Ceretec.

FAQs

Can stannous chloride be replaced in an exametazime kit?

A replacement reducing system may be technically possible, but it would require comparative data on labeling yield, radiochemical purity, stability, sterility, toxicity, and compatibility with sodium pertechnetate sources. The change could trigger a new formulation or bridging regulatory pathway.

Does exametazime require a preservative?

A preservative is generally undesirable for a sterile radiopharmaceutical kit intended for immediate or short-term use. Preservatives can affect compatibility, labeling chemistry, sterility strategy, and regulatory acceptability.

Can a lower-moisture lyophilized cake support patent protection?

Yes, if the lower-moisture specification is tied to an unexpected improvement in shelf life, stannous chloride stability, labeling yield, or radiochemical purity. Moisture limits without demonstrated technical effect are more vulnerable to obviousness objections.

Is a unit-dose exametazime kit commercially superior to a multi-dose vial?

It can reduce preparation errors, cross-contamination risk, and waste from unused material. Its disadvantages are higher packaging cost, lower flexibility in activity adjustment, and increased logistics requirements.

Could a hospital radiopharmacy prepare a competing exametazime product?

Potentially, subject to applicable drug manufacturing, compounding, radiopharmacy, sterility, radiation-safety, and regulatory requirements. Hospital preparation may compete with a commercial kit in limited settings but is unlikely to replicate the manufacturing consistency and distribution scale of an approved product.

References

1. U.S. Food and Drug Administration. (2019). Ceretec (technetium Tc 99m exametazime) kit for the preparation of technetium Tc 99m exametazime injection: Prescribing information. FDA.

2. GE Healthcare. (2019). Ceretec exametazime kit: Product information. GE Healthcare.

3. Health Canada. (n.d.). Drug Product Database. Government of Canada.

4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA and Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

5. United States Pharmacopeia. (n.d.). General chapter <823>: Positron emission tomography drugs for compounding, dispensing, and repackaging. United States Pharmacopeial Convention.